Myeloma Crowd and HealthTree have opened a COVID-19 Myeloma Patient Study. It is a series of questions that have been created by the Myeloma Crowd Multiple Myeloma Research Review Board. These myeloma experts and the Myeloma Crowd want to know how COVID-19 is affecting myeloma patients.
The anonymous answers will be aggregated and analyzed by myeloma researchers to identify recommendations that will help all myeloma patients know how best be protected and effectively treated for both COVID-19 and their myeloma. Their goal is to include 1,000 myeloma and precursor condition (MGUS and smoldering myeloma) patients and to provide reporting results quickly.
Each study participant will receive a free rapid COVID-19 antibody test. This is a finger prick blood test that identifies if you have developed coronavirus antibodies.This rapid test was used in a 3200 patient Stanford University study and has been verified in a CLIA (Clinical Laboratory Improvement Amendments) approved lab.
Please note that you must be registered with HealthTree to participate in the study. For more information, go to https://www.healthtree.org/